U.S. biotechnology firm Seagen Inc. is set to revive its quest for billions in damages in an ongoing legal dispute with Daiichi Sankyo Co. Ltd., a prominent Japanese drugmaker. This contention arises over the patenting of cancer drugs and Seagen alleges that an arbitrator has overlooked the intrinsic “language and essence” of a fundamental collaboration agreement between the two parties.
This dispute underscores the inherent complexities of legal entanglements within the biotechnology and pharmaceutical sectors, particularly when vast sums and patent rights are at stake. High-level collaboration agreements between corporations become focal points of contention when the interpretation and adherence to such agreements are in dispute.
In the wake of this development, the legal teams representing both Seagen and Daiichi Sankyo will be closely observed by the industry as they navigate the intricacies of this conflict. This case serves as a crucial reminder of the importance of precise language in legal agreements, particularly in high-stake collaborations such as this one involving cancer drug patenting.
For more in-depth press coverage of the Seagen-Daiichi dispute, click here to review the thoroughly researched piece by Caroline Simson on Law360.